Earnings Outlook For Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $-0.72. Historical data shows mixed reactions to past earnings, with the last quarter beating estimates but followed by a 17.05% drop in share price. Over the last year, RVNC shares have declined by 82.36%, indicating potential concern among long-term investors ahead of this earnings announcement.
February 27, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics is expected to report an EPS of $-0.72 for the upcoming quarter. Historical performance shows volatility in stock price post-earnings, with a significant drop after the last report despite beating estimates.
Given the historical performance where RVNC's stock price dropped significantly after beating EPS estimates last quarter, and the overall 82.36% decline over the past year, it's likely that the upcoming earnings report could lead to further short-term price declines, especially if the company fails to meet or exceed the EPS estimate or provides negative guidance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100